Introduction
============

Essential hypertension (EH) can be defined as a rise in blood pressure for unknown cause. It can increase risks for cerebral, cardiac, and renal events. It usually clusters with other cardiovascular risk factors such as aging, being overweight, insulin resistance, diabetes, and hyperlipidaemia ([@B29]; [@B40]). Human tribbles homolog 3 (*TRIB3*) is organized as four exons, encoding a 358-amino-acid protein. TRIB3 proteins disrupts insulin signaling by binding directly to Akt and blocking activation of the kinase, which contributes to insulin resistance and other physiological processes of vessel ([@B8]; [@B34]). AKT mediates the phosphatidylinositol 3′-kinase-protein kinase B-endothelial nitric oxide (NO) synthase (PI3K-AKT-eNOS)-dependent pathway in the cardiovascular protective effect of insulin, which is crucial for NO synthase activation, eventually leading to increased NO production, vasodilation and blood flow ([@B47]). Other signaling molecules such as bone morphogenetic proteins type II receptor (BMRPII) and bone morphogenetic proteins (BMP) also interact with TRIB3 and modulate the vascular effect ([@B21]; [@B43]; [@B3]). Accumulating evidences supported that some drugs or active materials affect vascular functions by regulating *TRIB3*. For example, the amiloride derivative phenamil promotes contractile phenotype of vascular smooth muscle cells (vSMCs) by activating *TRIB3* gene transcription ([@B4]; [@B19]). Homocysteine, which is significantly associated with hypertension could up-regulate the expression of *TRIB3*, thus leading to the endothelial dysfunction ([@B4]; [@B50]).

A single nucleotide polymorphism (SNP) variant in human *TRIB3* exon 2, which results in a glutamine (Q) to arginine (R) missense mutation in a conserved motif at position 84, confers stronger Akt binding, resulting in reduced Akt phosphorylation ([@B10]). Since Prudente S first reported the relationship between *TRIB3* missense Q84R (rs2295490) polymorphism and insulin resistance or its related cardiovascular events ([@B33]), numerous clinical studies have confirmed the risk of genetic variant associated with vascular events, especially the deleterious role of *TRIB3* R84 ([@B13]; [@B12]; [@B32]; [@B48]). Among patients with metabolic syndrome and the control group, patients with *TRIB3* RR84 genotype had significantly higher level of serum semaphorin 3E than those with QQ84 or QR84 genotypes ([@B35]), individuals with RR84 genotype also showed further decreased serum obestatin. Increased serum semaphorin 3E or decreased serum obestatin might in part exacerbate insulin resistance and carotid atherosclerosis ([@B7]). In human endothelial cells, data demonstrate that the *TRIB3* R84 variant impairs insulin signaling and NO production ([@B2]). These vascular disease-related studies suggested a possible link between *TRIB3* and EH.

Studies showed that imidapril mediated various actions, such as vasodilation, anticoagulation, hypotension, atherosclerosis and other cardiovascular protection via bradykinin-eNOS-NO pathway ([@B22]; [@B5]). Celiprolol triggered PI3K-Akt and increased eNOS expression ([@B23]), and doxazosin also increased the expression of *eNOS* accompanying with NO production via cAMP/cGMP/adrenalin signaling pathway ([@B39], [@B38]). Azelnidipine significantly increased *eNOS* expression levels in the brain as well as in the heart and aorta ([@B20]). Zhang, et al. demonstrated that valsartan significantly down-regulated the expression of *TRIB3* mRNA level and improved the cardiac function in rats with diabetic cardiomyopathy ([@B49]).

These data indicate that *TRIB3* has an integral role in regulating the blood pressure, and its genetic variation (251, A \> G) may cause a variability of antihypertensive drug therapy. Our previous findings have suggested a greater benefit on vascular outcomes in patients carrying *TRIB3* (rs2295490) G allele with good glucose and blood pressure control ([@B14]). *TRIB3* (rs2295490) AG/GG genotypes were found to reduce primary vascular events in patients who received intensive glucose treatment as compared to those receiving standard glucose treatment in type 2 diabetic patients ([@B16]). However, to our knowledge, there is no study to evaluate the association between *TRIB3* Q84R polymorphism and the effect of antihypertensive drugs in patients with EH.

Patients and Methods
====================

Patients
--------

The study protocol was approved by the Ethical Committee of the Institute of Clinical Pharmacology, Central South University (Hunan, China). Clinical study was registered at the Chinese Clinical Trial Register with the registration number ChiCTR-RO-12002612^[1](#fn01){ref-type="fn"}^. All the patients participating in the study were given written informed consent. The clinical data and DNA samples were graciously provided by Shanghai Institute of Hypertension, Ruijin Hospital affiliated with Shanghai Jiao Tong University. According to study design, all the patients fulfilled the following inclusion and exclusion criteria: male or female patients, heart rates within 55∼90 beats/min, systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg were included. Patients with secondary hypertension, coronary heart disease, diabetes, obesity (BMI.30 kg/m^2^), stroke, renal or liver dysfunction, malignant tumor or pregnancy and those whose blood pressure measurements above 180/110 mmHg or remaining lower than 140/90 mmHg during the wash-out period, were withdrawn from the study. In our study, a total of 368 unrelated subjects with primary mild to moderate EH, aged from 26 to 81 years were recruited for genetic screening. All the patients were enrolled after a run-in period of 2 weeks and assigned to receive the drugs for 4 weeks or more. The patients were followed up every 2 weeks at the weekend, and details of the protocol were shown in [Table 1](#T1){ref-type="table"}. According to the study protocol, 86 samples were excluded from 454 eligible patients due to the small sample size, not contactable and fail to meet inclusion criteria. At last, a total of 368 patients were included in our study. The medications include β-adrenoceptor antagonists (β-ADRs, atenolol, bisoprolol and celiprolol), α-adrenoceptor antagonist (α-ADR, doxazosin), calcium channel blockers (CCBs, azelnidipine and compound nitrendipine), ACE-inhibitor (ACEI, imidapril) and angiotensin receptor blocker (ARB, candesartan and irbesartan). All patients received monotherapy. Details are shown in [Figure 1](#F1){ref-type="fig"}.

###### 

The protocols of the related drugs to a total of 368 eligible patients in the study.

                                                                  Sample   Treatment   Case
  --------------------------------------------------------------- -------- ----------- ------------
  Celiprolol (200 mg/d)                                           54       6           ETW
  Atenolol (25 mmg/d)/ bisoprolol (5 mmg/d)                       39       4           EQW
  Doxazosin (2 mmg/d)                                             82       6           ETW
  Azelnidipine (2 mmg/d)/nitrendipine + atenolol (5 + 10 mmg/d)   73       6           ETW
  Candesartan (8 mmg/d) + irbesartan (150 mmg/d)                  50       6           ETW
  Imidapril (5 mmg/d)                                             70       6 or 8      ETW or EQW

N = number; W = week; ETW = every two weeks; EQW = every four weeks

.

![Study protocol and visit time to 368 patients with related drugs in the study. wk, week.](fphar-10-00236-g001){#F1}

Blood Pressure and Heart Rate Measurement
-----------------------------------------

Blood pressure determinations were performed on the morning after a light breakfast with subjects in the seated position and following a 30 min quiet resting period. Blood pressure and heart rate were measured by trained nurses, with an automatic blood pressure monitor with intellisense, which allows the detection of alteration of the heart rate by greater than or equal to beat/min and the blood pressure by greater than or equal to 1 mmHg. Detected results were then validated by supervisors with the mercury sphygmomanometer. The blood pressure values were determined by the average of three measurements taken every 10 min. Values of SBP and DBP were defined by Korotkoff phase I and V, respectively. Pulse pressure was calculated as PP = (SBP- DBP); mean arterial pressure (MAP) was calculated as MBP = DBP + (PP/3) ([@B42]).

Genotyping Procedure for *TRIB3*
--------------------------------

Tribbles homolog 3 (251, A \> G) genotypes were determined by sanger sequencing. The PCR primers for *TRIB3* (251, A \> G) were shown as follows: the sense primer, 5′GTTGCCCCTGAGCCCACCTACT3′; and the antisense primer, 5′TCCCTGGATGCTTCCCCACTAA3′. The product length was 286 bp. The reaction mixture (25 μl) contained: 10 × PCR buffer (2.5 μl), 10 × dNTP (2.5 μl), 10 μM for each of the sense and antisense primers (0.5 μl), H~2~O (16.8 μl), gDNA (2 μl), Taq polymerase (0.2 μl). Temperature cycling was proceeded as follows: initial denaturation for 5 min at 94°C, followed by 36 cycles of denaturation 30 s at 94°C, annealing at 57°C for 30 s, and elongation at 72°C for 30 s, and a terminal extension for 5 min. Genotypes were determined without knowledge of the status of patients, Ten percent blinded, random DNA samples from the patients were genotyped twice, with 100% concordance. And sequencing was assisted by Shanghai Majorbio Bio-pharm Technology Company.

Statistical Analysis
--------------------

All the analyses were performed with SPSS (version 19.0 for windows; Chicago, IL, United States). Allele frequencies were determined by the genotypes of all the participants. Continuous data were presented as mean values ± standard error (SE), and categorical variable was shown as frequencies and percentages. The Hardy--Weinberg equilibrium analysis was carried out for the genotypes of participants using the χ^2^-test. Difference in baseline characteristics among the phenotypes were assessed by independent-samples *T*-test.

The linear mixed model was used to examine the efficacy of *TRIB3* (251, A \> G). This allowed the use of time-dependent and time-independent covariates within the model to be analyzed. Furthermore, this model has been found to work well for small sample sizes with missing data ([@B31]; [@B6]). The outcome measures included ΔSBP, ΔDBP and ΔMAP. These measures were analyzed individually, with the main effects of genotype, follow-up time and their interaction, as well as subjects' intercept serving as random effects. The best fit model was decided after checking the smallest Akaike Information Criterion (AIC), and the Schwarz Bayesian Criterion (BIC) values. The covariance structure adopted for the final model was the Unstructured (UN) which means each variance and each covariance is estimated uniquely from the data. Models were additionally adjusted for the fixed effects of baseline age, sex, body mass index (BMI), SBP, DBP, total cholesterol, heart rate, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), fasting blood-glucose (FBG) and other biochemical factors appropriately. The linear mixed model analysis was done by using the PASW 19.0 for Windows (SPSS Inc., Chicago, IL, United States). Functions in nlme package of R statistical computing environment (R Foundation ---for Statistical Computing, Vienna, Austria) were used to confirm the analysis. Stratified Analysis was used to address whether significant interaction was present between age-genotype and sex-genotype. A two-tailed *P*-value \< 0.05 was considered significant.

Results
=======

Baseline Characteristics, Genotyping Results and Outline of Major Findings
--------------------------------------------------------------------------

In this study, 368 patients were genotyped unambiguously for *TRIB3* (251, A \> G) genetic variation. Our data showed that the frequency of *TRIB3* (251, A \> G) G allele was 18.5% in Chinese population. Genotype frequencies of *TRIB3* (251, A \> G) AA, AG and GG were 66.0, 31.0 and 3.0%, respectively. All the allele frequencies were in Hardy-Weinberg equilibrium (*P* \> 0.05). Owing to the low frequency of the GG genotype, we combined the AG and GG genotypes as one group for the following analysis. Baseline characteristics of the patients stratified by *TRIB3* genotypes are shown in [Table 2](#T2){ref-type="table"}. No significant differences between AA and AG+GG genotype groups in age, BMI, HR, BP or other clinical characteristics, such as FBG, triglyceride, cholesterol, HDL and LDL, etc. were observed.

###### 

Baseline characteristics of patients with essential hypertension stratified by *TRIB3* genotype.

  Variable       *TRIB3*             *P*-value           
  -------------- ------------------- ------------------- -------
  Age, year      57.0 ± 8.4(243)     56.5 ± 8.6(125)     0.524
  BMI, kg/m^2^   25.2 ± 3.0(242)     25.1 ± 3.6(125)     0.723
  HR, bpm        75.2 ± 7.5(243)     75.1 ± 7.3(125)     0.781
  SBP, mm Hg     149.3 ± 10.3(243)   151.2 ± 10.5(125)   0.485
  DBP, mm Hg     98.0 ± 4.3(243)     98.3 ± 4.8(125)     0.485
  MAP, mm Hg     115.1 ± 5.3(243)    115.9 ± 5.6(125)    0.388
  PP, mm Hg      51.3 ± 9.3(243)     52.8 ± 9.7(125)     0.100
  ALT, umol/L    31.5 ± 17.3(212)    31.8 ± 27.7(101)    0.336
  BUN, mmol/L    5.2 ± 1.2(222)      6.5 ± 9.3(109)      0.471
  UCr, mmol/L    79.8 ± 16.6(237)    79.1 ± 17.3(122)    0.610
  UA, mmol/L     320.4 ± 80.5(180)   328.1 ± 89.6(82)    0.246
  FBG, mmol/L    5.2 ± 0.98(210)     5.4 ± 1.2(105)      0.739
  TG, mmol/      1.78 ± 1.6(236)     2.33 ± 1.3(120)     0.653
  CHO, mmol/L    5.1 ± 1.0(237)      5.4 ± 1.3(121)      0.101
  HDL, μmol/L    1.4 ± 0.3(221)      1.4 ± 0.3(111)      0.740
  LDL, umol/L    3.4 ± 1.1(144)      3.6 ± 1.0(78)       0.374

Data expressed as mean ± SD. BMI indicates body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; ALT, alanine aminotransferase; BUN, blood urea nitrogen; UCr, urine creatinine; UA, uric acid; FBG, fasting blood-glucose; TG, triglyceride; CHO, cholesterol; HDL, high-density lipoprotein; LDL, low density lipoprotein

.

Different Pressure Response to *TRIB3* (251, A \> G) for Antihypertensive Drugs
-------------------------------------------------------------------------------

As shown in [Figure 2A](#F2){ref-type="fig"}, the DBP-change and MAP-change from baseline response to *TRIB3* (251, A \> G) variant was significantly reduced (AA genotype compared to AG/GG genotype carriers) after CCBs administration. A similar tendency of DBP-change and MAP-change was found for imidapril (ACEI) treatment ([Figure 2C](#F2){ref-type="fig"}), in which a marginally significant difference was achieved (*P* = 0.073 and 0.075, respectively). Inversely, DBP change from baseline after ARBs prescription was significantly increased for the AA genotype carriers compared to AG/GG genotype ([Figure 2B](#F2){ref-type="fig"}). In the stratified analysis, there were significant differences in BP-change (blood pressure, include SBP or DBP or MAP) of AG/GG carriers between older and younger age or male and female ([Supplementary Figures S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}). Nevertheless, no association between *TRIB3* (251, A \> G) genetic polymorphism and α-ADR or β-ADR drug response was observed in our study cohort ([Figure 3A,B](#F3){ref-type="fig"}).

![The relationship between *TRIB3* (251, A \> G) genetic polymorphism and the hypotensive effects of the antihypertensives monotherapy in EH patients. Panels **(A--C)** respectively depicts that BP-changes from baseline in EH patients carrying the *TRIB3* (251, A \> G) AA and AG/GG genotypes after treatment with the drugs of CCBs, ARBs and ACEIs for 6 weeks. *P*-value were calculated by the linear mixed model and adjusted for baseline age, BMI, gender, SBP, DBP, total cholesterol, heart rate, triglyceride, HDL, LDL, FBG and other biochemical factors appropriately. Error bar indicated 95% confidence interval.](fphar-10-00236-g002){#F2}

![The relationship between *TRIB3* (251, A \> G) genetic polymorphism and the hypotensive effects of α,β-ADRs monotherapy in EH patients. Panels **(A--C)** respectively depicts that BP- changes from baseline in EH patients carrying the *TRIB3* (251, A \> G) AA and AG/GG genotypes after treatment with α-ADR, β-ADR and α, β-ADRs for 6 weeks. *P*-value were adjusted for baseline age, BMI, gender, SBP, DBP, total cholesterol, heart rate, triglyceride, HDL, LDL, FBG and other biochemical factors appropriately. Error bar indicated 95% confidence interval.](fphar-10-00236-g003){#F3}

Age-, Sex-Dependent Manner Related to α, β-ADRs on Blood Response
-----------------------------------------------------------------

As studies showed that α, β-ADRs were all playing a role in the cAMP/cGMP/adrenalin signaling pathways to induce the transcription of eNOS in a time-dependent manner^\[18\]^, we combined α, β-ADRs treatment groups in the analysis model. However, there was no significant change between AG/GG and AA genotype in the linear mixed model ([Figure 3C](#F3){ref-type="fig"}). Stratified analysis was then used to explore the difference in SBP-, DBP-, MAP-change from baseline after α, β-ADRs therapy. In the sex stratification analysis, BP-change from baseline was significantly reduced for male compared to female in AG/GG genotype ([Figure 4](#F4){ref-type="fig"}). And in the analysis of age stratification, we took 50,55,60 as the boundaries for analysis respectively, and found that 55 was the most appropriate cut-off value. The results showed that people with age younger than 55 years old had more significant antihypertensive effects in AG/GG genotype carriers ([Figure 5](#F5){ref-type="fig"}).

![Blood pressure response to α,β-ADR blocker therapy in EH patients stratified by sex dependent of *TRIB3* genotype. Panels **(A--C)** respectively depicts that SBP-, DBP-, MAP- changes from baseline in EH patients carrying the *TRIB3* (251, A \> G) AA and AG/GG genotypes after treatment with α, β-ADRs for 6 weeks. *P*-value were adjusted for baseline age, BMI, SBP, DBP, total cholesterol, heart rate, triglyceride, HDL, LDL, FBG and other biochemical factors appropriately. Error bar indicated 95% confidence interval.](fphar-10-00236-g004){#F4}

![Blood pressure response to α,β-ADR blocker therapy in EH patients stratified by age-specific to TRIB3 genotype. Panels **(A--C)** respectively depicts that SBP-, DBP-, MAP- changes from baseline in EH patients carrying the *TRIB3* (251, A \> G) AA and AG/GG genotypes after treatment with α, β-ADRs for 6 weeks. *P*-value were adjusted for baseline BMI, gender, SBP, DBP, total cholesterol, heart rate, triglyceride, HDL, LDL, FBG and other biochemical factors appropriately. Error bar indicated 95% confidence interval. The stratification based on a boundary of age-55 showed the largest difference in blood pressure decrease after analysis of age-50, 55, 60.](fphar-10-00236-g005){#F5}

Discussion
==========

In this study we showed that *TRIB3* (251, A \> G) genetic variation had a significant clinical relevance to the efficacy of certain class of antihypertensive drugs in individuals with EH treatment. It has been demonstrated that a better effect on BP response was observed in *TRIB3* Q84R (rs2295490, 251 A \> G) AA genotype carriers than AG/GG carriers after taking a routine dosage of ACEI and CCBs antihypertensives. After stratification analysis for age and sex, we found a more significant difference between these two genotype carriers. Studies have shown that CCBs and ACEI have an excellent antioxidant stress effect via increasing eNOS expression and NO synthesis ([@B18]; [@B24]). *TRIB3*, has been identified affecting insulin action by binding to and inhibiting Akt phosphorylation, which also regulated eNOS and NO. In human and mice, insulin can relax bladder via activating PI3K-AKT-eNOS pathway and lead to a three folds increase in NO synthesis than baseline in AA-but not in *TRIB3* AG/GG genotype carriers ([@B26]). Meanwhile, insulin had almost no effect on NO synthesis for AG/GG genotype carriers in human umbilical vein endothelial cells ([@B2]). Taken together, our results are consistent with the deleterious role of *TRIB3* G allele on NO production, which may lead to a weaker response to ACEI and CCBs antihypertensives.

On the contrary, a better response to ARBs was found on AG/GG genotype carriers than AA genotype carriers. This phenomenon may be interpreted as the different mechanisms of Angiotensin. The published literature has reported that Ang-(1-7) can elevate blood pressure by promoting pro-inflammatory and pro-thrombotic effects. Moreover, Ang IV can activate AT4R, and may contribute to cardiac damage ([@B36]; [@B41]). Likewise, [@B46] has demonstrated that Ang IV increased blood pressure and reduced renal blood flow through counteracting the presence of AT2 receptors in mice. Other studies revealed that Ang IV can ameliorate AngII-induced cardiac injury via AT4R and protect against acute cerebral ischemia via Ang IV-AT4R, NO-dependent mechanisms ([@B9]; [@B45]). As mentioned above, an Ang-(1-7) triggered mechanism involving AT1R-, AT4R-, mass receptors and cGMP-PKG-NO pathway may cause the different antihypertensive effect of ACEI and ARB among individuals induced by *TRIB3* (251, A \> G) genetic polymorphism. In addition, ARB could down-regulate *TRIB3* mRNA level and a dual function of ARB on eNOS expression may also lead to the opposite relationship between *TRIB3* G allele and antihypertensive effects of ACEI and ARBs ([@B49]; [@B30]).

In the ARB and ACEI treatment groups, we noticed that the difference in antihypertensive efficacy between different carriers of *TRIB3* genotypes became more significant as time went on, which may be due to an increase in local eNOS mRNA expression and a decrease in angiotensin II in the LV, leading to the amelioration of myocardial remodeling in hypertensive condition ([@B22]). Reversed results of ARBs were also shown in the sex stratification. In this drug treatment group, female of AA genotype but not those with G allele have stronger antihypertensive efficacy compared to male. In the treatment of ACEIs, older (age ≥ 55) patients with AA genotype have stronger antihypertensive efficacy compared to younger patients (age \< 55). The specific mechanism needs more in-depth discussion and exploration.

In EH patients treated with α, β-ADRs, we did not observe significant difference of antihypertensive effect on response to *TRIB3* genotypes. However, it is interesting to note that *TRIB3* (251, A \> G) variance was associated with α, β-ADRs monotherapy in Chinese population with EH in an age-dependent and sex-specific manner. And between the age groups and the sex groups, there is a significant difference in BP-change from baseline only limited to patients with *TRIB3* (251, A \> G) AG/GG genotype, while the mechanism is unclear. In addition, our study has shown that among G allele carriers, males or youngers are more likely to have a better antihypertensive effect ([Figure 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). This may be attributed to the inconsistent distribution of adrenoceptor in a sex-dependent manner. The regulation of estrogen may also result in greater adrenoceptor blocker reactivity in males than in females ([@B28]; [@B1]). Researches showed that aging decreases cardiac beta-adrenergic responsiveness in model systems and in humans *in vivo* with multiple mechanisms including downregulation and decreased agonist binding of beta 1-receptors, uncoupling of beta 2-receptors, and abnormal G protein-mediated signal transduction ([@B44]).

Reduction in BP by 1--4 mm was also a question be worthy to think about, in the research of [@B27] a 2 mm Hg lower usual SBP was associated with approximately 10% lower stroke mortality and about 7% lower mortality from ischaemic heart disease or other vascular causes in middle age. In general, a 20 mm Hg difference in usual SBP is approximately equivalent in its hazards to a 10 mm Hg difference in usual DBP ([@B27]). Therefore, we make hypothesis that for every 1 mm Hg reduction in diastolic blood pressure in the general normotensive population, the mortality rate of vascular-related events can be reduced by 7--10%. For patients with high blood pressure, a decrease of several mmHg of BP may not bring such a big benefit, but we can still assume the benefit exists.

In recent years it became evident that the vast majority of genetic variants in genes of importance for drug treatment are rare, with minor allele frequencies \<1%. Also, recent approximations based on analyses of population-scale sequencing projects estimate that such rare variants account for 30--40% of the interindividual variability in drug response ([@B25]). Some low-frequency genetic variants detected by re-sequencing of *TRIB3* can partially account for cardiovascular clinical outcomes in diabetes. But the association was especially strong among individuals who also carried the common R84 variant ([@B32]). Other studies reported that the variation at 5′-untranslated region of the gene may have a strong impact on translational efficiency and serve an important function on gene expression regulating ([@B17]). Several additional infrequent nonsynonymous single-nucleotide polymorphisms have been identified in the genomic region encompassing the human *TRIB3* gene (dbSNP^[2](#fn02){ref-type="fn"}^) whose function and potential biological relevance have never, so far, been addressed. These may lead us to speculate that rare and common variants in *TRIB3* may act together to alter drug efficacy.

Our study was a well-controlled drug clinical trial in which patients received monotherapy. Nevertheless, some limitations should be considered in the interpretation of our findings. On the one hand, diet habits, lifestyle factors may affect the antihypertensive effect of drugs. Such as a daily mean of 30 min of vigorous exercise, a DASH style diet, modest alcohol intake up to 10 g/day, non-narcotic analgesic use less than once per week, and intake of 400 μg/day or more of supplemental folic acid may lead to lower risk of hypertension ([@B11]). These factors also have the potential to make patients have a distinguishing antihypertensive effect. However, our results do not exclude the influence of these factors because of the lack of these information. On the other hand, polymorphisms of other genes may also be involved in the interaction between heredity and drug efficacy or affect vascular function ([@B15]; [@B37]).

Conclusion
==========

In conclusion, the results of the present study suggest that the *TRIB3* (251, A \> G) polymorphism was associated with the response of antihypertensive drugs therapy in Chinese EH patients,. Although this data may prove *TRIB3* (251, A \> G) genetic variation is useful in clinical therapy, combining other genetic markers to identify individuals at high risk of cardiovascular abnormalities may bring a better clinical outcome. Further pharmacogenomics studies on *TRIB3* merit attention.
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###### 

Blood pressure response to CCBs, ARBs, and ACEI therapy in EH patients stratified by age-specific to TRIB3 genotype. **A--C** respectively depicts that BP changes from baseline in EH patients carrying the *TRIB3* (251, A\>G) AA and AG/GG genotypes after treatment with CCBs, ARBs, and ACEI for 6 weeks respectively. *P*-value were adjusted for baseline BMI, sex, SBP, DBP, total cholesterol, heart rate, triglyceride, HDL, LDL, FBG, and other biochemical factors appropriately. Error bar indicated 95% confidence interval. The stratification based on a boundary of age-55 showed the largest difference in blood pressure decrease after analysis of age-50, 55, 60.

###### 

Click here for additional data file.

###### 

Blood pressure response to CCBs, ARBs, and ACEI therapy in EH patients stratified by sex dependent of TRIB3 genotype. **A--C** respectively depicts that BP changes from baseline in EH patients carrying the *TRIB3* (251, A\>G) AA and AG/GG genotypes after treatment with CCBs, ARBs, and ACEI for 6 weeks respectively. *P*-value were adjusted for baseline age, BMI, SBP, DBP, total cholesterol, heart rate, triglyceride, HDL, LDL, FBG, and other biochemical factors appropriately. Error bar indicated 95% confidence interval.

###### 

Click here for additional data file.
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